Alimera Sciences Inc to Discuss Newly Issued Series C Preferred Stock Conference Call
שיחת ועידה Alimera Sciences Inc
Alimera Sciences Inc Conference call or earnings call will be held on 05/09/2018 via an 800 number (toll-free). During the earnings conference call's session Alimera Sciences Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Alimera Sciences Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
Alimera Sciences, Inc., and its subsidiaries (we, Alimera or the Company), is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because we believe these diseases are not well treated with current therapies and represent a significant market opportunity. Our only commercial product is ILUVIEN®, which has been developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN has received marketing authorization in the U.S., Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom.קרא עוד שיחת ועידה